Azienda Ospedaliera Ordine Mauriziano Di Torino

This hospital-based oncology program in Turin, Italy supports a broad portfolio of studies across neoplasms and related cancer care, with a strong focus on testing new treatment options and refining how patients are managed in routine practice. The research also reflects active work in blood cancers, solid tumors, and supportive care.

• Neoplasms and advanced cancer care, including studies in ovarian, endometrial, breast, gastric, pancreatic, and colorectal cancers
• Hemic and lymphatic diseases, with research in leukemia, lymphoma, myelodysplastic syndromes, and myelofibrosis
• Purpose: evaluating the effectiveness and safety of new therapies, as well as improving outcomes for patients with difficult-to-treat cancers

The site’s oncology team contributes to trials that compare new targeted and immune-based approaches with existing standards, helping advance more personalized cancer treatment.

A major area of research at this site is hematologic oncology, covering aggressive and chronic blood cancers such as acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, lymphoma, and myelodysplastic syndromes. These studies aim to improve remission rates, long-term disease control, and treatment options for patients with limited choices.

• Acute myeloid leukemia, including mutation-defined and secondary forms
• Acute lymphoblastic leukemia and chronic myeloid leukemia, with work on deeper molecular responses and treatment-free remission
• Myelofibrosis, myelodysplastic syndromes, and essential thrombocythemia, focusing on symptom control and blood count improvement
• Purpose: testing targeted therapies, combination strategies, and approaches that aim to improve remission durability and reduce relapse

The oncology department at Azienda Ospedaliera Ordine Mauriziano Di Torino is especially active in studies that seek more precise, biomarker-informed treatment for blood cancers.

The site also participates in research on digestive system diseases, especially Crohn’s disease, ulcerative colitis, and colorectal cancer, along with selected studies in gastric cancer and cholangiocarcinoma. This work spans both inflammatory bowel disease and gastrointestinal cancers, with an emphasis on better symptom control and improved disease outcomes.

• Crohn’s disease and ulcerative colitis, including studies of moderate to severe disease
• Colorectal cancer and gastric or gastroesophageal junction cancer
• Purpose: evaluating new therapies, comparing treatment strategies, and improving disease control in chronic inflammatory and cancer settings

These trials reflect a strong interest in both immune-mediated gut disease and gastrointestinal oncology, two areas where treatment advances can have a major impact on quality of life.

A substantial share of the research portfolio addresses female urogenital diseases and gynecological cancers, including ovarian cancer, endometrial cancer, cervical cancer, vulvar cancer, and related carcinosarcomas. These studies are designed to improve survival, delay progression, and expand options for patients with recurrent or advanced disease.

• Ovarian cancer, including platinum-resistant, recurrent, and biomarker-selected subtypes
• Endometrial cancer and cervical cancer, including advanced and recurrent forms
• Purpose: testing new targeted, immune-based, and combination approaches to improve response and prolong disease control

This is one of the most active therapeutic areas at the site, with research focused on difficult-to-treat cancers where better treatment sequencing and personalized care are especially important.

The clinical trial program also includes cardiovascular diseases, such as acute coronary syndrome, myocardial infarction, atrial fibrillation, hypertension, and other high-risk vascular conditions. These studies aim to improve prevention of major events, reduce complications, and optimize care after acute cardiac episodes or procedures.

• Acute myocardial infarction and acute coronary syndrome
• Atrial fibrillation and stroke prevention after left atrial appendage closure
• Purpose: assessing new cardiovascular treatments, antithrombotic strategies, and methods to reduce heart-related complications

Research in this area shows the site’s interest in both acute cardiac care and long-term cardiovascular risk reduction.

Beyond oncology, the site contributes to studies in immune system diseases such as systemic lupus erythematosus, psoriatic arthritis, thyroid eye disease, eosinophilic granulomatosis with polyangiitis, chronic spontaneous urticaria, and asthma. These trials focus on controlling inflammation, reducing flares, and improving daily symptoms for patients living with chronic immune-related conditions.

• Systemic lupus erythematosus and other autoimmune diseases
• Psoriatic arthritis, thyroid eye disease, and chronic spontaneous urticaria
• Purpose: evaluating new biologic and targeted therapies to improve symptom control and disease stability

These studies highlight a broader clinical research profile that extends beyond cancer into chronic inflammatory disease management.

The site’s solid tumor portfolio includes muscle-invasive bladder cancer, non-muscle invasive bladder cancer, metastatic breast cancer, triple-negative breast cancer, and selected studies in pancreatic cancer, prostate cancer, and lung cancer. Research in these areas is aimed at improving tumor control and expanding treatment choices for patients with advanced disease.

• Bladder cancer, including both early and more advanced disease settings
• Breast cancer and other metastatic solid tumors
• Purpose: testing novel oncology treatments and comparing them with established care to improve response and survival

The breadth of these studies shows a strong commitment to modern cancer research across multiple tumor types.